Epilepsy Gene-Edited Cell Lines for Drug Discovery and Functional Genomics

Epilepsy is one of the most common neurological disorders, affecting approximately 50 million people worldwide according to the World Health Organization (WHO, 2023). The global incidence is estimated at 2.4 million new cases per year. Epilepsy is characterized by recurrent, unprovoked seizures and can arise from genetic, structural, metabolic, or unknown causes. The disorder imposes a significant burden on quality of life, with increased risks of premature death, cognitive impairment, and psychiatric comorbidities. Despite the availability of over 30 antiseizure medications, approximately 30% of patients develop drug-resistant epilepsy, underscoring the urgent need for novel therapeutic targets and precision medicine approaches.

Epilepsy is an ideal disease for mechanistic studies using gene-edited cell models due to its well-defined genetic architecture. Over 900 genes have been associated with epilepsy (ClinVar, 2024), including ion channel genes (SCN1A, KCNQ2, KCNT1), neurotransmitter receptor genes (GABRG2, GRIN2A), and synaptic genes (SYNGAP1, STXBP1). Publicly available datasets from the Epilepsy Genetics Initiative (EGI) and the Epi25 Collaborative provide extensive sequencing data. Key open questions include the functional impact of specific variants, mechanisms of drug resistance, and the role of somatic mosaicism in focal epilepsies. Gene-edited cell models enable precise dissection of these mechanisms.

Epilepsy pathogenesis involves disruption of the delicate balance between neuronal excitation and inhibition. The major mechanisms include:

• • Ion channel dysfunction: Mutations in voltage-gated sodium (SCN1A, SCN2A), potassium (KCNQ2, KCNT1), and calcium (CACNA1A) channels alter neuronal excitability and action potential firing.
• • Synaptic transmission defects: Alterations in GABAergic (GABRG2, GABRA1) and glutamatergic (GRIN2A, GRIA2) receptors disrupt inhibitory and excitatory signaling.
• • Synaptic vesicle trafficking: Mutations in STXBP1, SYNGAP1, and DNM1 impair neurotransmitter release and synaptic plasticity.
• • mTOR pathway hyperactivation: Mutations in TSC1, TSC2, and DEPDC5 lead to aberrant mTOR signaling, causing cortical malformations and hyperexcitability.

Data from ClinVar (2024) and Epi25 consortium studies.

Key signaling networks implicated in epilepsy include:

• • mTOR signaling: Hyperactivation leads to abnormal neuronal morphology, synaptic plasticity changes, and seizure susceptibility. Key nodes: TSC1, TSC2, DEPDC5, NPRL2, NPRL3.
• • GABAergic signaling: Reduced GABA synthesis (GAD1, GAD2) or receptor function (GABRA1, GABRG2, GABRB3) decreases inhibitory tone.
• • Glutamatergic signaling: Overactivation of NMDA (GRIN2A, GRIN2B) and AMPA (GRIA2) receptors enhances excitotoxicity.
• • Synaptic vesicle cycle: STXBP1, SYNGAP1, and DNM1 regulate vesicle docking, fusion, and recycling; mutations disrupt synaptic transmission.

Organoids offer advantages over 2D cultures by recapitulating 3D neuronal networks, cell-type diversity, and synaptic connectivity, enabling study of network-level hyperexcitability.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines that differ only at the target locus, providing a clean genetic background for functional studies. Examples include:

• • SCN1A knockout in SH-SY5Y cells: Models loss-of-function in a human neuronal background.
• • KCNQ2 G279S knock-in in HEK293T: Recapitulates a common neonatal epilepsy mutation.
• • GABRG2 R43Q knock-in in iPSC-derived neurons: Models febrile seizure susceptibility.

Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house editing and validation. These models are available from commercial sources and can be used for electrophysiology, calcium imaging, and drug screening.

Gene-edited cell lines are essential for validating epilepsy-associated genes identified by genome-wide association studies (GWAS) and whole-exome sequencing. For example:

• • SCN1A knockout in iPSC-derived neurons confirmed loss of sodium current and reduced action potential firing in inhibitory interneurons.
• • STXBP1 knockout in SH-SY5Y cells demonstrated impaired synaptic vesicle exocytosis and reduced neurotransmitter release.
• • DEPDC5 knockout in HEK293T cells led to mTOR pathway hyperactivation, confirming its role in focal epilepsy.

Isogenic cell pairs (wild-type vs. mutant) enable high-throughput screening for compounds that selectively rescue the mutant phenotype. Examples:

• • SCN1A mutant neurons: Screened for sodium channel modulators that restore interneuron firing.
• • KCNQ2 mutant cells: Used to identify potassium channel openers (e.g., retigabine analogs) that compensate for loss of M-current.
• • Drug resistance modeling: GABRG2 mutant lines can be used to test whether specific antiseizure medications (e.g., benzodiazepines) lose efficacy due to receptor dysfunction.

CRISPR-based synthetic lethality screens in epilepsy gene-edited cells can identify novel therapeutic targets. For example:

• • In SCN1A knockout neurons, a genome-wide CRISPR screen identified genes whose loss reduces hyperexcitability, revealing potential drug targets.
• • In TSC2-deficient cells, screens for mTOR pathway dependencies have identified downstream effectors (e.g., S6K1, 4E-BP1) as biomarkers of disease activity.